⇚ Regimen OPDIVO® and YERVOY® - for Non Small Cell Lung Cancer Medical Name OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) - for advanced NSCLC Cycles Given N/A Delivery Phases N/A Special Instructions Both OPDIVO® and YERVOY® are administered for 2 years or until disease progression or unacceptable toxicity. Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis, Nephritis and Endocrinopathies. References Hellmann MD, et al. NEJM 2019 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration OPDIVO® (Nivolumab) IV 3 mg/kg D1 q14 NSS 250 cc 60 minutes YERVOY® (Ipilimumab) IV 1 mg/kg D1 q42 NSS 250 cc 60 minutes